Semaglutide Halves Diabetes Obesity Risk

Mitchel L. Zoler, PhD

Treatment of people with obesity but without diabetes using the glucagon-like peptide-1 (GLP-1) agonist semaglutide (Wegovy) led to beneficial changes in body mass index (BMI), glycemic control, and other clinical measures.

This collectively cut the calculated risk for possible future development of type 2 diabetes in study participants by more than half, based on post-hoc analysis of data from two pivotal trials that compared semaglutide with placebo.

The findings “suggest that semaglutide could help prevent type 2 diabetes in people with overweight or obesity,” said W. Timothy Garvey, MD, in a presentation at the European Association for the Study of Diabetes 2022 Annual Meeting.

To support the writing of useful articles about endocrinology, ClinicalPosters sells human anatomy charts, scientific posters and other products online. Slide extra posters into DeuPair Frames without removing from the wall or leave an encourag­ing comment to keep the work going. Visible content is optimized for device size.

Updated: Oct 24, 2022

Join Discussion